Last reviewed · How we verify

DBV712 — Competitive Intelligence Brief

DBV712 (DBV712) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Epicutaneous immunotherapy (EPIT). Area: Immunology / Allergy.

phase 3 Epicutaneous immunotherapy (EPIT) Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

DBV712 (DBV712) — DBV Technologies. DBV712 is an epicutaneous immunotherapy (EPIT) that delivers allergen to the immune system through the skin to induce immune tolerance.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DBV712 TARGET DBV712 DBV Technologies phase 3 Epicutaneous immunotherapy (EPIT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Epicutaneous immunotherapy (EPIT) class)

  1. DBV Technologies · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DBV712 — Competitive Intelligence Brief. https://druglandscape.com/ci/dbv712. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: